Overview

Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency

Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This study is intended to assess the effects of once daily dosing of recombinant human insulin-like growth factor (rhIGF-1) in increasing height velocity.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Ipsen
Treatments:
Insulin
Insulin, Globin Zinc
Mecasermin
Mitogens